Substituted indazole derivatives active as kinase inhibitiors

Patent metadata

Field	Value
Publication number	US-10028934-B2
Application number	US-201615203092-A
Country	US
Kind code	B2
Filing date	Jul 6, 2016
Priority date	May 12, 2011
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

First claim

The invention claimed is:

1. A method of treating a disease caused by and/or associated with a degulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I)

wherein:
Ar is a group selected from

wherein:
R1 is an optionally substituted heterocyclyl;
R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, SO n R9, COR10, NR11R12, OR13 or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, straight or branched C 2 -C 6 alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and heterocyclyl wherein:
R9 is NR11R12 or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, straight or branched C 2 -C 6 alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl and heteroaryl;
R10 is hydrogen, NR11R12, OR13 or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, straight or branched C 2 -C 6 alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl and heteroaryl;
R11 and R12, taken together with the nitrogen atom to which they are bound, may form an optionally substituted heterocyclyl group;
R13 is hydrogen, COR10 or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, straight or branched C 2 -C 6 alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein R10 is as defined above;
n is 0, 1 or 2;
X is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl;
Y is a bond or oxygen;
Z is an optionally substituted straight or branched C 1 -C 6 alkyl;
Ar′ is an optionally substituted aryl or an optionally substituted heteroaryl;
or a pharmaceutically acceptable salt thereof,
wherein said disease is selected from the group consisting of acute myeloid leukaemia, colon adenocarcinoma, lung cancer, gastrointestinal stromal tumor and rhabdomyosarcoma.

2. The method according to claim 1 wherein the mammal in need thereof is a human.

3. The method according to claim 1 wherein the cancer is a FLT3 mutated cancer.

4. The method according to claim 1 wherein the cancer is a KIT mutated cancer.

5. The method according to claim 1 which provides tumor angiogenesis and metastasis inhibition.

6. The method according to claim 1 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

7. An in vitro method for inhibiting FLT3 or KIT protein kinase activity which comprises contacting the said protein with an effective amount of a compound of formula (I) as defined in claim 1 .

8. The method according to claim 1 wherein, in the compound of formula (I):
Ar is a group Ar1 or Ar2, in which R1 is an optionally substituted heterocyclyl, and R2, R3, R4 and R5 are independently hydrogen, halogen, NR11R12 or OR13;
Y is oxygen;
Ar′ is an optionally substituted aryl or an optionally substituted heteroaryl;
or a pharmaceutically acceptable salt thereof.

9. The method according to claim 8 wherein, in the compound of formula (I):
Ar is a group Ar1, in which R1 is an optionally substituted heterocyclyl and R2, R3, R4 and R5 are hydrogen;
Ar′ is an optionally substituted aryl;
or a pharmaceutically acceptable salt thereof.

10. The method according to claim 9 wherein, in the compound of formula (I):
Ar is a group Ar1, in which R1 is optionally substituted piperazine;
Ar′ is aryl optionally substituted with halogen or a halogen-substituted alkyl;
or a pharmaceutically acceptable salt thereof.

11. The method according to claim 10 wherein, in the compound of formula (I):
R1 is methyl-substituted piperazine;
Ar′ is aryl substituted with a halogen-substituted alkyl;
or a pharmaceutically acceptable salt thereof.

Assignees

• Nerviano Medical Sciences Srl

Inventors

• Lombardi Borgia Andrea
• Ciomei Marina
• Donati Daniele
• Nesi Marcella

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• C12N9/12

  transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title